An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells

Clinical and Experimental Immunology

Volumn 114, Issue 2, 1998, Pages 173-178

  Eberl, G ^a   Jiang, S ^a   Yu, Z ^a   Schneider, P ^a   Corradin, G ^a   Mach, J P ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

B cell lymphoma; CD19; CD4+ T cell; Cytotoxicity; Fas

Indexed keywords

CD19 ANTIGEN; FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; PERFORIN; TETANUS TOXIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG CONJUGATION; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CYTOTOXICITY TESTS, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; PEPTIDES; TETANUS TOXIN;

EID: 0031789486     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00710.x     Document Type: Article

References (49)

1. 2 fragments. J Clin Invest 1989; 83:1449-56.
2. Mach JP, Pèlegrin A, Buchegger F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol 1991; 3:685.
3. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988; 48:6396.
4. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med 1996; 2:350-3.
5. Aboud Pirak E, Hurwitz E, Bellot F, Schlessinger J, Sela M. Inhibition of human tumour growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor. Proc Natl Acad Sci USA 1989; 86:3778-81.
6. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48:2641-58.
7. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 1982; 306:517-22.
8. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. New Engl J Med 1985; 312: 1658-65.
9. Kehrl JH, Riva A, Wilson GL, Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 1994; 15:432.
10. Hekman A, Honselaar A, Vuist W et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol 1991; 32:364-72.
11. Uckun FM, Evans WE, Forsyth CJ et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995; 267:886.
12. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69:584-91.
13. 131I anti-Ba (anti-CD20) antibody. New Engl J Med 1993; 329:459-65.
14. Press OW, Eary JF, Appelbaum FR et al. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl J Med 1993; 329:1219-24.
15. Maloney DG, Grillo-Lopez A, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-95.
16. Brissink J, Demanet C, Moser M, Oberdan L, Thielemans K. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 1991; 147:4019-26.
17. Ochi A, Migita K, Xu J, Siminovitch K. In vivo tumor immunotherapy by a bacterial superantigen. J Immunol 1993; 151:3180-6.
18. Hansson J, Ohlsson L, Persson R, Andersson G, Ilback NG, Litton MJ. Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci USA 1997; 94:2489-94.
19. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996; 93:7826-31.
20. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19:2237-42.
21. Yu Z, Healy F, Valmori D, Escobar P, Corradin G, Mach JP. Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int J Cancer 1994; 56:244-8.
22. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymph 1995; 18:385-97.
23. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996; 14:207-32.
24. Osborne BA. Apoptosis and the maintenance of homoeostasis in the immune system. Curr Opin Immunol 1996; 8:245-54.
25. Atherton E, Logan CJ, Sheppard RC. Procedures for solid phase synthesis using Na-fluorenylmethoxycarbonylamino-acids on polyimide supports. Synthesis of substance P and of acyl carrier protein 65-74 decapeptide. J Chem Soc Perkin Trans 1981; 1:538-46.
26. Lowin B, Mattman C, Hahne M, Tschopp J. Comparison of Fas (Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes. Int Immunol 1996; 8:57-63.
27. Booth RJ, Grandison PM, Prestidge RL, Watson JD. The use of a 'universal' yeast expression vector to produce an antigenic protein of Mycobacterium leprae. Immunol Letters 1988; 19:65-69.
28. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dorken B, Moldenhauer G. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 1988; 167:345-52.
29. Maryanski JL, Pala P, Cerottini J-C, Corradin G. Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA. J Exp Med 1988; 167:1391-405.
30. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (Lond) 1995; 377:348-51.
31. + T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 1997; 158:2756-61.
32. + T cells. J Immunol 1997; 159:2091-9.
33. + T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297-322.
34. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995; 25:2303-7.
35. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Ann Rev Immunol 1993; 11:403-50.
36. Jondal M, Schirmbeck R, Reinmann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity 1996; 5:295-302.
37. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17:131-7.
38. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-40.
39. Versteeg R, Kruse-Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, Ruiter DJ, Schrier PI. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 1989; 170:621-35.
40. + T cells by B7-transfected melanoma cells. Science 1993; 259:368-70.
41. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6.
42. Dutcher JP. Therapeutic strategies for cytokines. Curr Opin One 1995; 7:566-71.
43. Tahara H, Zitvogel L, Storkus WJ et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1994; 154:6466-74.
44. Pesando JM, Bouchard LS, McMaster BE. CD19 is functionally and physically associated with surface immunoglobulin. J Exp Med 1989; 170:2159-64.
45. Knight SC, Stagg AJ. Antigen-presenting cell types. Curr Opin Immunol 1993; 5:374-82.
46. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995; 146:57-79.
47. Trinchieri G. Interleukin-12: a proinflammmatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adapitive immunity. Annu Rev Immunol 1995; 13:251-76.
48. Muller C, Tschopp J. Resistance of CTL to perforin-mediated lysis. Evidence for a lymphocyte membrane protein interacting with perforin. J Immunol 1994; 153:2470-8.
49. Romero P, Eberl G, Casanova J-L, Cordey A-S, Widmann C, Luescher JF, Corradin G, Maryanski JL. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. J Immunol 1992; 148:1871-8.